Cronos Group (TSE:CRON) Price Target Raised to C$5.50 at TD

Cronos Group (TSE:CRON) had its target price hoisted by investment analysts at TD from C$4.50 to C$5.50 in a note issued to investors on Tuesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. TD’s target price points to a potential upside of 45.50% from the stock’s previous close.

Several other brokerages have also recently issued reports on CRON. TD Securities set a C$4.50 price objective on Cronos Group and gave the company a “buy” rating in a research note on Tuesday, February 24th. Canaccord Genuity Group set a C$4.25 price objective on Cronos Group and gave the company a “buy” rating in a research note on Tuesday, January 27th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of C$4.75.

Cronos Group Stock Up 0.8%

CRON traded up C$0.03 on Tuesday, reaching C$3.78. The company’s stock had a trading volume of 149,066 shares, compared to its average volume of 169,266. The stock has a market cap of C$1.42 billion, a price-to-earnings ratio of -189.00, a price-to-earnings-growth ratio of 0.12 and a beta of 1.12. Cronos Group has a 1 year low of C$2.54 and a 1 year high of C$4.66. The company has a debt-to-equity ratio of 0.25, a current ratio of 19.59 and a quick ratio of 24.01. The business’s 50 day moving average is C$3.56 and its 200 day moving average is C$3.60.

Cronos Group (TSE:CRON) last issued its quarterly earnings results on Monday, May 11th. The company reported C$0.06 EPS for the quarter. The firm had revenue of C$62.86 million during the quarter. Cronos Group had a negative return on equity of 0.87% and a negative net margin of 6.37%. As a group, research analysts forecast that Cronos Group will post -0.26 EPS for the current fiscal year.

Cronos Group Company Profile

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.